Barings’s AstraZeneca AZN Stock Holding History

Barings’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$23.6M	Sell	126,110 -16,922	-12%	-$3.18M	0.42%	31
2026 Q1	$27.8M	Buy	+143,032	New	+$27.6M	0.45%	26

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Barings's AZN Position: Q2 2026 in Review

Barings reduced its AstraZeneca (AZN) stake by 12% in Q2 2026, selling an estimated $3.18M and leaving 126,110 shares worth $23.6M. The position accounts for 0.42% of the portfolio, ranked #31.

Barings first reported a position in AZN in Q1 2026 and has held it in 2 quarters since. The position peaked at $27.8M in Q1 2026. 1,502 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

Barings held 126,110 shares of AstraZeneca worth $23.6M as of Q2 2026.
Barings sold 16,922 AstraZeneca shares in Q2 2026, an estimated $3.18M.
AstraZeneca made up 0.42% of Barings's portfolio in Q2 2026, its #31 holding.
Barings first reported a position in AstraZeneca in Q1 2026 and has held it in 2 quarters since.
Barings's AstraZeneca position peaked at $27.8M in Q1 2026.
1,502 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Barings's 13F filing for Q2 2026, filed 7 Aug 2026.